Related Experiment Video
Updated: Feb 10, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Approaches to Left Atrial Appendage Closure: Device Design, Performance, and Limitations
Amish S Dave1, Miguel Valderrábano1
1METHODIST DEBAKEY HEART & VASCULAR CENTER, HOUSTON METHODIST HOSPITAL, HOUSTON, TEXAS.
Insights
Atrial fibrillation (AF) increases stroke risk. Novel left atrial appendage (LAA) closure devices offer an alternative to anticoagulants, potentially reducing stroke risk in AF patients.
Area of Science:
- Cardiology
- Medical Devices
- Stroke Prevention
Background:
- Atrial fibrillation (AF) affects millions, significantly raising stroke risk.
- Oral anticoagulants are standard for stroke prevention but have limitations like bleeding risk.
- Most AF-related strokes originate from the left atrial appendage (LAA).
Purpose of the Study:
- To review percutaneous left atrial appendage (LAA) closure strategies for stroke prevention in AF.
- To examine the benefits and drawbacks of LAA closure devices.
- To explore future directions in managing AF-related stroke risk.
Main Methods:
- Review of existing studies on LAA closure devices.
- Analysis of percutaneous strategies for LAA occlusion.
- Examination of clinical outcomes and safety profiles.
Main Results:
- LAA closure is a promising alternative to anticoagulation for stroke prevention in AF.
- Various percutaneous devices are available for LAA closure.
- These devices aim to reduce stroke risk by excluding the LAA as a source of emboli.
Conclusions:
- Percutaneous LAA closure presents a viable option for patients with AF who are unsuitable for anticoagulation.
- Further research and device development are ongoing to optimize stroke prevention in AF.
- LAA closure strategies hold significant potential for reducing the burden of AF-related strokes.
Abstract:
Up to 6.1 million people in the United States have atrial fibrillation (AF), which is associated with an increased risk of stroke. Oral anticoagulants are the mainstay of stroke prevention in AF. For decades, warfarin was the only available drug, fraught with compliance limitations, a narrow therapeutic window, and a high risk of hemorrhage. Pharmacologic developments have produced new anticoagulants that have improved the rates of stroke related to AF; however, they still confer a high risk of bleeding, making them unsuitable for some patients. Studies have shown that roughly 90% of strokes in patients with AF occur in the left atrial appendage (LAA). This understanding has prompted the development and testing of novel percutaneous strategies for LAA closure as an alternative to anticoagulation therapy. The following review examines the relative merits and shortcomings of these strategies and explores future prospects in the prevention of AF-related stroke.
Related Concept Videos
Dosage Regimens: Designs and Approaches
Surface Appendages of Archaea
Group Design
Limiting Reactant
Factorial Design
The Number e as a Limit

